Autologous stem cell transplantation for newly diagnosed multiple myeloma – real-world data from 2,149 Czech patients publication / By Serafim Nenarokov
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma publication / By Serafim Nenarokov
Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma publication / By Serafim Nenarokov
The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance publication / By Serafim Nenarokov
Isatuximab, bortezomib, lenalidomide, dexamethasone for multiple myeloma: dynamics of MRD-negativity in the IMROZ study publication / By Serafim Nenarokov
Winners take it all: turning cell competition into a therapeutic ally publication / By Serafim Nenarokov
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH) publication / By David Žihala
Selective depletion of B-cell subsets underlies increased risk of infection in MM patients treated with anti-BCMA vs -GPRC5D bsAbs publication / By David Žihala
Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials publication / By David Žihala
